Literature DB >> 8844486

Simultaneous development of Crohn's disease and myelodysplastic syndrome progressing to acute myelocytic leukemia in a patient with a normal karyotype.

T Tani1, Y Sakai, Y Shirai, M Ohtake, K Hatakeyama.   

Abstract

A 28-year-old man developed Crohn's disease and myelodysplastic syndrome concurrently. Chromosomal analysis of the bone marrow revealed a normal male karyotype. Subsequently, the myelodysplastic syndrome progressed to acute myelocytic leukemia. Several causes, including the medical treatment for Crohn's disease, chromosomal abnormalities, and a common underlying immune dysfunction, have been proposed as pathogenetic factors in the association with Crohn's disease of hematologic malignancies. This case suggests that neither medical treatment for Crohn's disease nor chromosomal abnormalities are inevitable causes of the development of hematologic malignancies associated with Crohn's disease. At present, the cause of the association remains unclear, although the idea of a common immune dysfunction is attractive.

Entities:  

Mesh:

Year:  1996        PMID: 8844486     DOI: 10.1007/bf02355065

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  17 in total

1.  The association between the myelodysplastic syndromes and Crohn disease.

Authors:  C Eng; F A Farraye; L N Shulman; M A Peppercorn; C M Krauss; J M Connors; R M Stone
Journal:  Ann Intern Med       Date:  1992-10-15       Impact factor: 25.391

2.  Cutaneous vasculitis in patients with myelodysplasia.

Authors:  A R Green; D Shuttleworth; D T Bowen; D P Bentley
Journal:  Br J Haematol       Date:  1990-03       Impact factor: 6.998

Review 3.  The myelodysplastic syndromes: biology and implications for management.

Authors:  A F List; H S Garewal; A A Sandberg
Journal:  J Clin Oncol       Date:  1990-08       Impact factor: 44.544

4.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

5.  Acute leukemia following inflammatory bowel disease.

Authors:  S B Hanauer; K K Wong; P H Frank; D L Sweet; J B Kirsner
Journal:  Dig Dis Sci       Date:  1982-06       Impact factor: 3.199

6.  Diagnostic radiation--a possible factor in malignancy in patients with chronic inflammatory bowel disease.

Authors:  A G Rogers; J Faintuch; A M Sourkes; D V Cormack
Journal:  Gastroenterology       Date:  1978-08       Impact factor: 22.682

7.  Infection in the myelodysplastic syndromes.

Authors:  C Pomeroy; M M Oken; R E Rydell; G A Filice
Journal:  Am J Med       Date:  1991-03       Impact factor: 4.965

8.  Proposals for the classification of the myelodysplastic syndromes.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1982-06       Impact factor: 6.998

9.  Inflammatory bowel disease and leukemia.

Authors:  E M Cohn; B Pearlstine
Journal:  J Clin Gastroenterol       Date:  1984-02       Impact factor: 3.062

10.  Inflammatory bowel disease and leukemia. A report of seven cases of leukemia in ulcerative colitis and Crohn's disease and review of the literature.

Authors:  S H Mir Madjlessi; R G Farmer; J K Weick
Journal:  Dig Dis Sci       Date:  1986-10       Impact factor: 3.199

View more
  2 in total

Review 1.  Concurrent inflammatory bowel disease and myelodysplastic syndrome: report of nine new cases and a review of the literature.

Authors:  Zhifeng Wang; Yanhua Zhou; Yulan Liu
Journal:  Dig Dis Sci       Date:  2007-12-14       Impact factor: 3.199

Review 2.  Hematological malignancies in chronic inflammatory bowel diseases: report of five cases and review of the literature.

Authors:  Pietro Crispino; Roberta Pica; Erika Angelucci; Adriana Consolazio; Margherita Rivera; Claudio Cassieri; Paolo Paoluzi
Journal:  Int J Colorectal Dis       Date:  2006-10-07       Impact factor: 2.796

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.